厄贝沙坦联合黄芪注射液对老年糖尿病肾病患者结缔组织生长因子的影响

被引：18

作者：

刘珊

张明霞

杨晓芬

刘伦志

机构：

[1] 湖北民族学院附属民大医院肾内科

来源：

中国老年学杂志 | 2015年 / 35卷 / 01期

关键词：

厄贝沙坦; 黄芪注射液; 糖尿病肾病(DN); 结缔组织生长因子(CTGF);

D O I：

暂无

中图分类号：

R587.2 [糖尿病性昏迷及其他并发症];

学科分类号：

100201 [内科学];

摘要：

目的观察厄贝沙坦+黄芪注射液对老年糖尿病肾病(DN)患者的血清及尿液中结缔组织生长因子(CTGF)的影响及临床意义。方法早期DN患者据治疗方案随机分为厄贝沙坦组、黄芪注射组、厄贝沙坦+黄芪注射组和对照组各28例。比较4组治疗疗效、血糖、肾功能相关指标及血清、尿液CTGF水平差异。结果 4组治疗有效率有显著差异(χ2=29.97,P<0.01),厄贝沙坦+黄芪组有效率最高;治疗前4组空腹血糖(FPG)、糖化血红蛋白(Hb A1c)、尿微量白蛋白排泄率(UAER)、血肌酐(Scr)、血清CTGF及尿液CTGF水平无统计学差异(P>0.05),而治疗后4组FPG(F=10.24,P<0.01)、Hb A1c(F=9.873,P<0.01)、UAER(F=39.68,P<0.01)、Scr(F=13.43,P<0.01)、血清CTGF(F=64.24,P<0.01)、尿液CTGF(F=49.53,P<0.01)均有显著差异,且均为对照组水平最高,厄贝沙坦+黄芪组最低。结论厄贝沙坦联合黄芪注射液能够显著降低DN老年患者的血清、尿液CTGF含量,对于DN的疗效更佳。

引用

页码：108 / 110

页数：3

共 9 条

[1]

GLUT1 Regulation of the Pro-Sclerotic Mediators of Diabetic Nephropathy [J].

Heilig, Charles W. ;

Deb, Dilip K. ;

Abdul, Afu ;

Riaz, Hasan ;

James, Leighton R. ;

Salameh, Jamal ;

Nahman, N. Stanley, Jr. .

AMERICAN JOURNAL OF NEPHROLOGY, 2013, 38 (01) :39-49

[2]

Effect of catalpol on diabetic nephropathy in rats.[J].Zhao Dong;Chang Xun Chen.Phytomedicine.2013,

[3]

DNA Aptamer Raised Against AGEs Blocks the Progression of Experimental Diabetic Nephropathy [J].

Kaida, Yusuke ;

Fukami, Kei ;

Matsui, Takanori ;

Higashimoto, Yuichiro ;

Nishino, Yuri ;

Obara, Nana ;

Nakayama, Yosuke ;

Ando, Ryotaro ;

Toyonaga, Maki ;

Ueda, Seiji ;

Takeuchi, Masayoshi ;

Inoue, Hiroyoshi ;

Okuda, Seiya ;

Yamagishi, Sho-ichi .

DIABETES, 2013, 62 (09) :3241-3250

[4]

Connective tissue growth factor, matrix regulation, and diabetic kidney disease [J].

McLennan, Susan V. ;

Abdollahi, Maryam ;

Twigg, Stephen M. .

CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (01) :85-92

[5]

SOD1, but not SOD3, deficiency accelerates diabetic renal injury in C57BL/6-Ins2Akita diabetic mice [J].

Fujita, Hiroki ;

Fujishima, Hiromi ;

Takahashi, Keiko ;

Sato, Takehiro ;

Shimizu, Tatsunori ;

Morii, Tsukasa ;

Shimizu, Takahiko ;

Shirasawa, Takuji ;

Qi, Zhonghua ;

Breyer, Matthew D. ;

Harris, Raymond C. ;

Yamada, Yuichiro ;

Takahashi, Takamune .

METABOLISM-CLINICAL AND EXPERIMENTAL, 2012, 61 (12) :1714-1724

[6]

Hemizygous deletion of CTGF/CCN2 does not suffice to prevent fibrosis of the severely injured kidney [J].

Falke, Lucas L. ;

Dendooven, Amelie ;

Leeuwis, Jan Willem ;

Nguyen, Tri Q. ;

van Geest, Rob J. ;

van der Giezen, Dionne M. ;

Broekhuizen, Roe ;

Lyons, Karen ;

Stoop, Reinout ;

Kemperman, Hans ;

Schlingemann, Reinier ;

Joles, Jaap A. ;

Goldschmeding, Roel .

MATRIX BIOLOGY, 2012, 31 (7-8) :421-431

[7]

Preventive effects of rutin on the development of experimental diabetic nephropathy in rats.[J].Hui-hui Hao;Zhu-min Shao;Dao-quan Tang;Qian Lu;Xu Chen;Xiao-xing Yin;Jing Wu;Hui Chen.Life Sciences.2012, 19-2

[8]

Clinical significance of inflammatory and fibrogenic cytokines in diabetic nephropathy [J].

El Mesallamy, Hala O. ;

Ahmed, Hanaa H. ;

Bassyouni, Atef A. ;

Ahmed, Amira S. .

CLINICAL BIOCHEMISTRY, 2012, 45 (09) :646-650

[9]

Extracellular matrix-associated (GAGs; CTGF); angiogenic (VEGF) and inflammatory factors (MCP-1; CD40; IFN-γ) in type 1 diabetes mellitus nephropathy.[J].Olga Ellina;Antonios Chatzigeorgiou;Sophia Kouyanou;Maria Lymberi;Christina Mylona-Karagianni;Emmanouil Tsouvalas;Elli F. Kamper.Clinical Chemistry and Laboratory Medicine.2011, 1

← 1 →